Accessible HCV Care Intervention for People Who Inject Illicit Drugs (PWID)
| Status: | Recruiting |
|---|---|
| Conditions: | Hepatitis, Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 7/20/2018 |
| Start Date: | July 20, 2017 |
| End Date: | July 1, 2022 |
| Contact: | Yesenia Aponte-Melendez |
| Email: | aponte-melendez@ndri.org |
| Phone: | (646) 653-3841 |
Accessible Care Intervention for Engaging People Who Inject Illicit Drugs in HCV Care
The proposed study will examine the feasibility, acceptability, safety, effectiveness, and
cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID)
in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs
designed specifically for PWID where they can comfortably access care without fear of shame
or stigma. Accessible Care will be provided by co-locating a hepatitis treatment provider,
together with a Hepatitis C Care Coordinator (HCCC), on-site at a collaborating needle
exchange program. The proposed study will compare the effectiveness of Accessible Care with
Usual Care (referrals to existing services) in facilitating linkage, engagement, and
retention of PWID in care for hepatitis C, addiction, and HIV prevention. The primary outcome
is sustained virologic response, which constitutes virologic cure. Substance use and HIV and
HCV risk behaviors are secondary outcomes.
cost of an Accessible Care intervention for engaging people who inject illicit drugs (PWID)
in hepatitis C care. Accessible Care for PWID is low-threshold care provided in programs
designed specifically for PWID where they can comfortably access care without fear of shame
or stigma. Accessible Care will be provided by co-locating a hepatitis treatment provider,
together with a Hepatitis C Care Coordinator (HCCC), on-site at a collaborating needle
exchange program. The proposed study will compare the effectiveness of Accessible Care with
Usual Care (referrals to existing services) in facilitating linkage, engagement, and
retention of PWID in care for hepatitis C, addiction, and HIV prevention. The primary outcome
is sustained virologic response, which constitutes virologic cure. Substance use and HIV and
HCV risk behaviors are secondary outcomes.
Inclusion Criteria:
1. 18 years or older,
2. injected heroin, cocaine, or other drugs in the past 90 days.
3. test HCV Ab and RNA positive
4. provide written consent (including consent for researchers to examine their hepatitis
C medical records)
Exclusion Criteria:
Persons already in care for hepatitis C, defined as having had at least 2 visits with a
hepatitis treatment provider within the past 6 months, will be excluded.
People with decompensated cirrhosis will be excluded.
We found this trial at
1
site
Click here to add this to my saved trials
